Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × rubitecan × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6 Thoracic 1 Sarcoma 1 Dermatologic 1 Breast 1

Conditions

Interventions

aldesleukin 65 Cyclophosphamide 48 fludarabine phosphate 33 fludarabine 30 Interleukin-2 25 incomplete Freund's adjuvant 21 Specimen Handling 18 Magnetic Resonance Spectroscopy 18 Ipilimumab 18 Biopsy 18 MART-1 Antigen 13 CTLA-4 Antigen 13 sargramostim 12 montanide ISA 51 12 Sorafenib 12 Nivolumab 11 Filgrastim 11 pembrolizumab 10 Interferon-alpha 10 Bevacizumab 9 trametinib 8 Temozolomide 8 temsirolimus 7 dabrafenib 7 Sirolimus 7 tanespimycin 6 Dacarbazine 6 Cisplatin 6 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 6 cabozantinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00005875 2013-12-04

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡